<DOC>
	<DOCNO>NCT00519805</DOCNO>
	<brief_summary>RATIONALE : Anticoagulants , dalteparin , may help prevent blood clot form patient lung cancer . It yet know whether dalteparin effective preventing blood clot patient lung cancer . PURPOSE : This randomized phase III trial study well dalteparin work prevent blood clot patient lung cancer .</brief_summary>
	<brief_title>Dalteparin Preventing Blood Clots Patients With Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether addition dalteparin result improve survival . Secondary - Determine venous thrombotic event-free survival metastasis-free survival . - Determine serious adverse event patient treated drug . - Determine toxicity drug patient . - Determine quality life , breathlessness , anxiety , depression patient treat drug . - Determine cost effectiveness cost utility drug . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I ( control ) : Patients receive anticancer treatment consider appropriate local medical team . - Arm II : Patients receive anticancer treatment consider appropriate local medical team . Beginning start first definitive anticancer treatment , patient receive dalteparin subcutaneously daily 24 week . Quality life , anxiety , depression , dyspnea assess baseline , 12 24 week , 9 12 month . After completion therapy , patient follow 9 month , 1 year , every 6 month least 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathological cytological diagnosis primary bronchial carcinoma ( small cell nonsmall cell lung cancer ) within past 6 week No intrathoracic tumor ( e.g. , carcinoid tumor , mesothelioma , lymphoma , lung metastasis another primary site ) No clinically apparent brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 03 Platelet count ≥ 100,000/mm³ Serum creatinine ≤ 150 µmol/L Willing able selfadminister dalteparin daily subcutaneous injection administer caregiver Not pregnant nursing Fertile female patient must use effective contraception ( sexually active ) No hemorrhagic stroke within past 3 month No know bleeding disorder No hemoptysis CTC ≥ grade 2 ( i.e. , symptomatic hemoptysis require medical intervention ) No central venous catheter require use thromboprophylaxis No known hypersensitivity dalteparin , heparin , low molecular weight heparin ( e.g. , history confirm suspect immunologically mediate heparininduced thrombocytopenia ; acute gastroduodenal ulcer ; subacute endocarditis ) No prior illness likely interfere study treatment comparison PRIOR CONCURRENT THERAPY : No prior treatment likely interfere study treatment comparison More 12 month since prior concurrent therapeutic anticoagulation No concurrent ketorolac ( Toradol® )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>thromboembolism</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
</DOC>